Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
---|
Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
---|---|---|---|---|---|---|---|---|
Q4 2024 | 103 | $541M | +$102M | -$125M | -$23M | TEVA, BBIO, SNY, SNDX, AZN | 13F-HR | 2/14/2025, 02:33 PM |
Q3 2024 | 108 | $610M | +$137M | -$136M | +$886K | TEVA, SNY, BBIO, SNDX, AMZN | 13F-HR | 11/14/2024, 03:15 PM |
Q2 2024 | 110 | $610M | +$168M | -$126M | +$42.6M | BBIO, SNY, CYTK, AMZN, SNDX | 13F-HR | 8/14/2024, 03:36 PM |
Q1 2024 | 93 | $617M | +$179M | -$175M | +$4.35M | TEVA, SNY, NICE, CYTK, SNDX | 13F-HR | 5/15/2024, 03:42 PM |
Q4 2023 | 89 | $533M | +$155M | -$214M | -$58.3M | TEVA, SNY, CYTK, NVMI, SNDX | Restatement | 2/15/2024, 07:40 AM |
Q3 2023 | 75 | $417M | +$80.8M | -$86.1M | -$5.3M | SNY, AZN, JNJ, MRK, AMZN | 13F-HR | 11/14/2023, 03:54 PM |
Q2 2023 | 76 | $467M | +$102M | -$121M | -$18.4M | SNY, AZN, JNJ, NICE, AMZN | 13F-HR | 8/14/2023, 03:45 PM |
Q1 2023 | 75 | $462M | +$241M | -$86.2M | +$154M | SNY, NICE, AZN, JNJ, TEVA | 13F-HR | 5/15/2023, 04:14 PM |
Q4 2022 | 58 | $318M | +$51.5M | -$359M | -$308M | AZN, SNY, JNJ, SNDX, MRK | 13F-HR | 2/14/2023, 03:36 PM |
Q3 2022 | 65 | $565M | +$201M | -$156M | +$44.5M | AZN, LLY, SNY, JNJ, MRK | 13F-HR | 11/14/2022, 04:20 PM |
Q2 2022 | 50 | $527M | +$141M | -$170M | -$29.5M | AZN, JNJ, LLY, SNY, ABBV | 13F-HR | 8/15/2022, 03:32 PM |
Q1 2022 | 59 | $597M | +$151M | -$361M | -$210M | AZN, JNJ, SNY, ABBV, PFE | 13F-HR | 5/16/2022, 03:34 PM |
Q4 2021 | 85 | $842M | +$218M | -$403M | -$185M | ABBV, AZN, SNY, LLY, MRK | 13F-HR | 2/14/2022, 03:24 PM |
Q3 2021 | 107 | $1.01B | +$351M | -$350M | +$235K | LLY, AZN, ABBV, PFE, SNY | 13F-HR | 11/15/2021, 03:41 PM |
Q2 2021 | 121 | $1.05B | +$259M | -$356M | -$97.1M | AZN, JNJ, MRK, SNY, GNRC | 13F-HR | 8/16/2021, 06:15 PM |
Q1 2021 | 158 | $1.09B | +$463M | -$305M | +$158M | LLY, JNJ, ABBV, MRK, SNY | 13F-HR | 5/17/2021, 06:01 AM |
Q4 2020 | 104 | $963M | +$386M | -$406M | -$20.1M | LLY, MRK, JNJ, NVS, BMY | 13F-HR | 2/16/2021, 06:29 AM |
Q3 2020 | 89 | $864M | +$255M | -$267M | -$12.3M | MRK, ABBV, JNJ, SNY, AZN | 13F-HR | 11/12/2020, 06:59 AM |
Q2 2020 | 80 | $840M | +$344M | -$211M | +$132M | ABBV, MRK, SNY, AZN, JNJ | 13F-HR | 8/13/2020, 06:02 AM |
Q1 2020 | 75 | $604M | +$200M | -$258M | -$57.3M | MRK, JNJ, BMY, SNY, NVO | 13F-HR | 5/14/2020, 07:49 AM |
Q4 2019 | 81 | $754M | +$218M | -$251M | -$32.4M | JNJ, BMY, SNY, MRK, NVO | 13F-HR | 2/13/2020, 12:11 PM |
Q3 2019 | 79 | $647M | +$242M | -$202M | +$39.8M | BMY, JNJ, GILD, MRK, SNY | 13F-HR | 11/14/2019, 06:01 AM |
Q2 2019 | 84 | $660M | +$181M | -$231M | -$50.1M | JNJ, ALXN, BMY, MRK, AZN | 13F-HR | 8/14/2019, 06:02 AM |
Q1 2019 | 2 | $0 | $0 | $0 | New Holdings | 6/20/2019, 07:37 AM | ||
Q1 2019 | 98 | $724M | +$233M | -$215M | +$17.9M | BMY, JNJ, FOLD, ALXN, MRK | 13F-HR | 5/15/2019, 06:23 AM |
Q4 2018 | 98 | $551M | +$184M | -$220M | -$36.5M | MYL, MRK, BMY, CELG, FOLD | 13F-HR | 2/14/2019, 06:42 AM |
Q3 2018 | 111 | $764M | +$291M | -$180M | +$111M | MRK, MYL, JNJ, GSK, BMY | 13F-HR | 11/14/2018, 12:39 PM |
Q2 2018 | 107 | $619M | +$230M | -$232M | -$1.72M | MRK, MYL, GSK, GILD, SHPG | 13F-HR | 8/13/2018, 08:30 AM |
Q1 2018 | 104 | $573M | +$188M | -$232M | -$43.6M | MRK, SHPG, CELG, FOLD, MYL | 13F-HR | 5/10/2018, 08:44 AM |
Q4 2017 | 130 | $618M | +$201M | -$132M | +$69M | CELG, MYL, MRK, BIIB, SRPT | 13F-HR | 2/12/2018, 02:44 PM |
Q3 2017 | 121 | $551M | +$145M | -$118M | +$26.7M | CELG, BIIB, MRK, GILD, GSK | Restatement | 11/27/2017, 10:57 AM |
Q2 2017 | 119 | $476M | +$167M | -$83.2M | +$83.7M | CELG, BIIB, MRK, GSK, GILD | 13F-HR | 8/9/2017, 10:08 AM |
Q1 2017 | 104 | $373M | +$146M | -$112M | +$33.9M | CELG, BIIB, NVS, MRK, SRPT | 13F-HR | 5/11/2017, 06:08 AM |
Q4 2016 | 98 | $321M | +$80.3M | -$180M | -$99.9M | MRK, CELG, TEVA, ALXN, CLCD | 13F-HR | 2/13/2017, 08:44 AM |
Q3 2016 | 101 | $434M | +$137M | -$74.7M | +$61.9M | MRK, TEVA, SRPT, AGN, LLY | 13F-HR | 11/14/2016, 07:46 AM |
Q2 2016 | 83 | $329M | +$121M | -$143M | -$21.5M | TEVA, AGN, GILD, LLY, CELG | 13F-HR | 8/10/2016, 10:17 AM |
Q1 2016 | 82 | $355M | +$90.1M | -$176M | -$86.2M | PFE, TEVA, BIIB, AGN, GILD | 13F-HR | 5/16/2016, 06:17 AM |
Q4 2015 | 112 | $510M | +$138M | -$168M | -$29.8M | TEVA, PFE, BIIB, AGN, ABBV | 13F-HR | 2/11/2016, 09:46 AM |
Q3 2015 | 118 | $499M | +$152M | -$202M | -$50.1M | AGN, TEVA, BIIB, PFE, ABBV | 13F-HR | 11/16/2015, 06:05 AM |
Q2 2015 | 121 | $644M | +$230M | -$295M | -$65M | AGN, GILD, PFE, ABBV, BIIB | 13F-HR | 8/6/2015, 01:19 PM |
Q1 2015 | 136 | $679M | +$322M | -$230M | +$91.8M | B108PS, PFE, GILD, TEVA, ABBV | 13F-HR | 5/11/2015, 06:43 AM |
Q4 2014 | 117 | $528M | +$168M | -$282M | -$114M | NVS, B108PS, PFE, TEVA, SLXP | 13F-HR | 2/12/2015, 12:42 PM |
Q3 2014 | 117 | $594M | +$305M | -$97.3M | +$208M | NVS, PFE, TEVA, B108PS, MRK | Restatement | 11/20/2014, 07:33 AM |
Q2 2014 | 86 | $369M | +$145M | -$167M | -$22.5M | NVS, MRK, TEVA, JNJ, PFE | Restatement | 8/20/2014, 06:03 AM |
Q1 2014 | 99 | $391M | +$196M | -$94.4M | +$102M | NVS, GSK, MRK, PFE, JNJ | 13F-HR | 5/14/2014, 12:02 PM |
Q4 2013 | 87 | $278M | $0 | $0 | GSK, PFE, XLF, MRK, SHPG | 13F-HR | 2/13/2014, 02:03 PM |